Work with LifeSpan to design a custom immunohistochemistry to address your specific biological question. Outsource the entire localization process without having to
worry about finding and characterizing target specific antibodies, sourcing and validating difficult-to-find tissues, and having the ability to interpret the resulting
immunostaining in relation to complex human pathologies.
TCR Screening Services
Test your therapeutic antibodies in immunohistochemistry against a broad panel of normal frozen human tissue types in order to determine potential unintended binding.
Our non-GLP TCR services are designed on the FDA recommendation outlined in their "Points to Consider in the Manufacture and Testing of Monoclonal Antibody Products for Human Use".
Description: The cysteinyl leukotrienes (CysLTs), LTC4 and LTD4, are potent mediators of asthma and hypersensitivity. They induce bronchoconstriction, increase microvascular permeability, and are vasoconstrictors of coronary arteries. Their biological effects are transduced by a pair of G protein-coupled receptors, CysLT1 and CysLT2. Montelukast (sodium salt) is a potent, selective cysteinyl leukotriene 1 (CysLT1) receptor antagonist sold under the trade name Singulair for the treatment of asthma as well as for the symptoms associated with allergic rhinitis. It binds to the human CysLT1 receptor with an IC50 of less than 5 nM with no appreciable binding to the CysLT2 receptor.
1-[[[(1R)-1-[3-(1E)-2-(7-chloro-2-quinolinyl)ethenyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]thio]-methyl]-cyclopropaneacetic acid, monosodium salt
Montelukast (sodium salt) is supplied as a crystalline solid. A stock solution may be made by dissolving the montelukast (sodium salt) in the solvent of choice. Montelukast (sodium salt) is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide, which should be purged with an inert gas. The solubility of montelukast (sodium salt) in these solvents is approximately 30 mg/ml. It is also soluble in water at a concentration of 10 mg/ml. Montelukast (sodium salt) is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, montelukast (sodium salt) should first be dissolved in ethanol and then diluted with the aqueous buffer of choice. Montelukast (sodium salt) has a solubility of approximately 0.15 mg/ml in a 1:9 solution of ethanol:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.